Susan J. Aluise

Susan J. Aluise

Susan J. Aluise is president and executive editor of National News Syndicate, a Washington, D.C.-based news organization focused on global business, national security, information technology, transportation and financial services. Prior to forming the company in January 1996, she spent a decade at Potomac, Md.-based Phillips Business Information — the last six years as editorial director. She has launched 31 subscription-based news publications and websites in the Aviation, Financial Services, Defense, Information Technology and Telecom industries, including Aviation Today, World Airport Week, Credit Risk Management Report and Electronic Commerce Insider. In a journalism career spanning more than 30 years, Susan has covered six U.S. presidents and 15 Congresses for a variety of U.S. and global news organizations. She also has covered several international political and economic summits and was honored by a national journalism foundation for excellence in news and analysis following the 9/11 terror attacks.

Recent Articles

4 Reasons Lower Fuel Prices Won’t Lift Airlines

But US Airways' stock is poised to buck the industry headwinds. One big reason: The growing odds that it will acquire American Airlines out of bankruptcy.

3 Hospital Stocks for a Healthy Portfolio

No matter if Obamacare thrives or gets thrashed, these name should prosper because they're making moves now that will pay off down the road either way.

Which Is Healthier, CVS or Walgreen?

WAG lags after the loss of Express Scripts, but acquiring Rite Aid could restore its health.

Is GM Being Penny Wise and Pound Foolish?

Pulling its Super Bowl and Facebook ads will save money, but it could make it tougher for the carmaker to compete with aggressive global rivals.

3 ETF Strategies to ‘Greek-Proof’ Your Money

As Greece edges ever closer to default, there’s plenty of gloom and doom to go around. Protect your portfolio with these three ETF tips.

Gilead Sciences’ HIV Drugs Clear a Hurdle

Full FDA approval should come next -- but if not, watch out, because Gilead is very heavily dependent on its HIV drug lineup, and patents will be expiring.

3 ETF Strategies to Ride Out Summer Volatility

With care, these ETFs are better than just selling in May because they can compensate for -- or even profit from -- the season's increased volatility.

Beauty Stocks: 3 to Buy, 3 to Leave

This month has been wild for beauty shares. It's time to turn to the Socratic principle: Question everything.

America’s 10 Most Powerful Female CEOs

Only 39 companies in the Fortune 1000 are female-led, but that list includes several powerful firms. Here's a look at the 10 biggest companies helmed by women.

Why Delta’s Oil Refinery May Not Have Wings

Trying to ensure a more plentiful and cheaper fuel supply is a bold move, but there's a lot of devilish stuff in the complex arrangement's details.